Other News To Note

• Arrowhead Research Corp., of Pasadena, Calif., said that it entered into an agreement with Merck & Co. Inc., through a subsidiary, to evaluate a novel therapeutic monoclonal antibody candidate derived from its human-derived peptide targeting and discovery program, which was acquired through the purchase of Alvos Therapeutics in April.